Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezafungin for chronic pulmonary aspergillosis in adults with limited treatment options
NL-OMON60679Phase 2Completed
- Sponsor
- Mundipharma
- Start
- Jul 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rezafungin in chronic pulmonary aspergillosis (CPA), sponsored by Mundipharma. Primary endpoints: St George's Respiratory Questionnaire response at 6 months, Weight change at 6 months and 1 more. Started Jul 2025; status: completed.
02
Drugs
rezafungin
03
Conditions
chronic pulmonary aspergillosis (CPA)
Beyond the preview
Go deeper on NL-OMON60679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60679.